Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals, Inc. - Common Stock
(NQ:
APLS
)
41.03
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals
↗
April 29, 2025
Via
Benzinga
Apellis Announces Craig Wheeler to Join the Board of Directors
April 21, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
↗
April 01, 2025
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.
Via
Benzinga
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
April 01, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views
↗
March 03, 2025
Via
Benzinga
What 6 Analyst Ratings Have To Say About Apellis Pharmaceuticals
↗
February 13, 2025
Via
Benzinga
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre
↗
March 18, 2025
JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered.
Via
Benzinga
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
↗
March 05, 2025
JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025.
Via
Benzinga
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
February 28, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 28, 2025
↗
February 28, 2025
Via
Benzinga
Analyst Expectations For Apellis Pharmaceuticals's Future
↗
January 21, 2025
Via
Benzinga
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings)
↗
December 17, 2024
Via
Benzinga
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
February 20, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
February 14, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
↗
November 21, 2024
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
January 27, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces Keli Walbert to Join the Board of Directors
January 10, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 07, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
December 23, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
December 17, 2024
Via
Benzinga
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
↗
December 17, 2024
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 27, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
↗
November 19, 2024
Via
Benzinga
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
November 12, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
November 06, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
